Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25

Canaccord biotech analyst to hold a dinner meeting

In conjunction with the 58th Annual ASH Meeting, Biotech Analyst Newman hosts a Key Opinion Leader Dinner Meeting with Jae Park, MD, who discusses the implications for Juno Therapeutics (JUNO), Kite Pharma (KITE), bluebird bio (BLUE) and Novartis (NVS), on December 3 at 10 pm.

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

  • 03

    Dec

  • 03

    Dec

JUNO Juno Therapeutics
$20.43

0.53 (2.66%)

12/01/16
LEER
12/01/16
NO CHANGE
LEER
Outperform
bluebird bio data looks 'impressive,' says Leerink
Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.
11/25/16
MAXM
11/25/16
NO CHANGE
Target $34
MAXM
Buy
Juno still has significant opportunity in 'no-option population,' says Maxim
Maxim analyst Jason McCarthy removed JCAR015 in adult ALL from his model for Juno Therapeutics after the company placed its ROCKET study on clinical hold for the second time following two additional patient deaths. Accordingly, the analyst lowered his price target on Juno shares to $34 from $50. However, McCarthy keeps a Buy rating on Juno shares, as he still believes CAR-T technology, and the company, has a "significant opportunity in the no-option population" and that regulators will agree when evaluating treatments intended to help patients that will otherwise die.
11/28/16
LEER
11/28/16
NO CHANGE
Target $34
LEER
Outperform
Juno Therapeutics price target lowered to $34 from $45 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Juno Therapeutics to $34 from $45 following news that the pivotal ROCKET trial of its JCAR015 product candidate in adult acute lymphocytic leukemia has been placed on a clinical hold due to safety concerns. The analyst believes the future of the program is now increasingly uncertain as the company's management is trying to better understand the therapeutic window of JCAR015, raising the question of whether it moved into a pivotal trial too fast. Schmidt reiterates an Outperform rating on the shares.
11/29/16
ADAM
11/29/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma benefits from program delays at Juno, says Canaccord
Canaccord analyst John Newman believes Kite Pharma (KITE) will benefit from the program delays at Juno Therapeutics (JUNO). Two deaths in Juno's Phase 2 ROCKET trial may prompt safety questions for its drug to be used in refractory NHL, which raises the upside potential for Kite when its presents its data at the ASH conference. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
KITE Kite Pharma
$50.76

0.04 (0.08%)

11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
BLUE bluebird bio
$69.75

1.1 (1.60%)

12/01/16
PIPR
12/01/16
NO CHANGE
PIPR
Overweight
bluebird bio BCMA CAR-T results early, but encouraging, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer noted that bluebird bio's interim data from its ongoing Phase 1 study of bb2121, the company's investigational anti-BCMA CAR-T candidate in patients with relapsed/refractory multiple myeloma, showed that four of nine patients achieved partial responses and two patients achieved stringent complete responses. While results are early, they are also encouraging, said Schimmer, who has an Overweight rating on bluebird shares.
12/01/16
BMOC
12/01/16
NO CHANGE
BMOC
bluebird bio data 'impressive,' says BMO Capital
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
12/02/16
MAXM
12/02/16
NO CHANGE
Target $87
MAXM
Buy
bluebird bio price target raised to $87 from $57 at Maxim
Maxim analyst Jason McCarthy said the early data on bluebird bio's bb2121 show it is inducing clinical responses, including complete responses, "essentially in the absence of" CRS and neuro-toxicity. While waiting to see if this trend continues, given the positive bb2121 data so far in multiple myeloma, McCarthy raised his price target on bluebird shares to $87 from $57. He keeps a Buy rating on the stock, noting that he is now factoring in a bb2121 launch in 2021.
NVS Novartis
$68.17

0.42 (0.62%)

11/10/16
ARGS
11/10/16
UPGRADE
ARGS
Buy
Novartis upgraded to Buy from Hold at Argus
11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
RHCO
11/30/16
NO CHANGE
RHCO
GlycoMimetics has positive read through from deal, says SunTrust
SunTrust analyst Yatin Suneja says that Novartis' (NVS) recent acquisition of Selexys Pharmaceuticals "provides further clinical and commercial validation for the selectin class of adhesion molecules as meaningful therapeutic targets." The analyst notes that the acquisition came after Selexys' SelG1, which utilizes a P-selectin antibody, showed positive Phase II data in sickle cell disease. GlycoMimetics (GLYC) develops selectin antagonists. The analyst expects interest in the name to accelerate as more data is announced. Suneja keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

ELLO

Ellomay Capital

$8.05

0.0019 (0.02%)

14:33
04/30/17
04/30
14:33
04/30/17
14:33
Hot Stocks
Ellomay Capital enters agreement to acquire Talasol Solar »

Ellomay Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos NV

$86.86

0.87 (1.01%)

14:23
04/30/17
04/30
14:23
04/30/17
14:23
Hot Stocks
Galapagos presents preclinical data on osteoarthritis candidate GLPG1972 »

Galapagos announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

SO

Southern Company

$49.80

-0.27 (-0.54%)

, TOSBF

Toshiba, also use TOSYY

$2.03

0.06 (3.05%)

14:16
04/30/17
04/30
14:16
04/30/17
14:16
Hot Stocks
Southern Co subsidiary extends interim agreement for Vogtle nuclear expansion »

Georgia Power and…

SO

Southern Company

$49.80

-0.27 (-0.54%)

TOSBF

Toshiba, also use TOSYY

$2.03

0.06 (3.05%)

TOSYY

Toshiba, also use TOSBF

$12.14

0.25 (2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

CG

Carlyle Group

$17.70

0.2 (1.14%)

14:10
04/30/17
04/30
14:10
04/30/17
14:10
Hot Stocks
Sequa completes recapitalization with participation from Carlyle Group »

Sequa Corp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$160.29

-0.03 (-0.02%)

14:07
04/30/17
04/30
14:07
04/30/17
14:07
Hot Stocks
IBM says granted patent for drone package transfer »

IBM announced Friday that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRAM

Grana y Montero

$3.37

0.07 (2.12%)

14:05
04/30/17
04/30
14:05
04/30/17
14:05
Hot Stocks
Grana y Montero completes sale of PRINSUR stake for $25M »

Grana y Montero announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$43.15

0.14 (0.33%)

13:49
04/30/17
04/30
13:49
04/30/17
13:49
Hot Stocks
Coca-Cola Bottling UNITED says closes Georgia transaction with Coca-Cola »

Coca-Cola Bottling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

VZ

Verizon

$45.91

-0.76 (-1.63%)

, T

AT&T

$39.63

-0.28 (-0.70%)

13:06
04/30/17
04/30
13:06
04/30/17
13:06
Periodicals
Business tax cut would favor telecoms, retailers, other sectors, Barron's says »

Sectors favored under a…

VZ

Verizon

$45.91

-0.76 (-1.63%)

T

AT&T

$39.63

-0.28 (-0.70%)

JPM

JPMorgan

$87.00

-0.61 (-0.70%)

COF

Capital One

$80.38

-1.93 (-2.34%)

CMA

Comerica

$70.70

-0.05 (-0.07%)

GPS

Gap

$26.20

-0.15 (-0.57%)

JWN

Nordstrom

$48.27

-0.03 (-0.06%)

BRK.A

Berkshire Hathaway

$247,780.00

-2170 (-0.87%)

BRK.B

Berkshire Hathaway

$165.21

-1.34 (-0.80%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

  • 09

    May

  • 16

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

CMG

Chipotle

$474.47

-7.53 (-1.56%)

12:59
04/30/17
04/30
12:59
04/30/17
12:59
Periodicals
Chipotle remains unattractive, Barron's says »

Investors should continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$61.34

-0.06 (-0.10%)

, ANTM

Anthem

$177.89

-0.41 (-0.23%)

12:45
04/30/17
04/30
12:45
04/30/17
12:45
Periodicals
Express Scripts contract-loss warning suggests further pain, Barron's says »

Express Scripts'…

ESRX

Express Scripts

$61.34

-0.06 (-0.10%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

CVS

CVS Health

$82.44

-0.35 (-0.42%)

UNH

UnitedHealth

$174.88

0.25 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

LITE

Lumentum

$42.75

-1.05 (-2.40%)

, OCLR

Oclaro

$8.01

0.08 (1.01%)

12:38
04/30/17
04/30
12:38
04/30/17
12:38
Periodicals
Bargain-priced fiberoptic space looks attractive, Barron's says »

Fiberoptic stocks…

LITE

Lumentum

$42.75

-1.05 (-2.40%)

OCLR

Oclaro

$8.01

0.08 (1.01%)

NPTN

NeoPhotonics

$7.76

-0.19 (-2.39%)

FNSR

Finisar

$22.84

0.27 (1.20%)

ACIA

Acacia Communications

$45.84

-0.76 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 04

    May

  • 05

    May

  • 09

    May

  • 09

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 30

    May

COH

Coach

$39.39

-0.43 (-1.08%)

12:14
04/30/17
04/30
12:14
04/30/17
12:14
Periodicals
Coach could reserve course, Barron's says »

Retail accessory makers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

, PG

Procter & Gamble

$87.33

-0.36 (-0.41%)

12:08
04/30/17
04/30
12:08
04/30/17
12:08
Periodicals
Bargain-priced Edgewell could attract suitor, Barron's says »

Edgewell Personal Care…

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

PG

Procter & Gamble

$87.33

-0.36 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

NEE

NextEra Energy

$133.56

0.04 (0.03%)

11:58
04/30/17
04/30
11:58
04/30/17
11:58
Periodicals
NextEra Energy could return 20% in a year, Barron's says »

NextEra Energy appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CAT

Caterpillar

$102.26

-0.42 (-0.41%)

11:52
04/30/17
04/30
11:52
04/30/17
11:52
Periodicals
Caterpillar shares 'back on track' for price gains, Barron's says »

Caterpillar is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    Jun

RYN

Rayonier

$28.22

-0.39 (-1.36%)

, LL

Lumber Liquidators

$24.55

0.19 (0.78%)

08:21
04/30/17
04/30
08:21
04/30/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

RYN

Rayonier

$28.22

-0.39 (-1.36%)

LL

Lumber Liquidators

$24.55

0.19 (0.78%)

DEL

Deltic Timber

$77.37

-2.24 (-2.81%)

WY

Weyerhaeuser

$33.87

-0.8 (-2.31%)

OSB

Norbord

$31.07

0.23 (0.75%)

PCH

Potlatch

$45.05

-1.9 (-4.05%)

UFPI

Universal Forest

$95.29

-1.92 (-1.98%)

AA

Alcoa

$33.73

-0.79 (-2.29%)

KALU

Kaiser Aluminum

$84.41

-0.15 (-0.18%)

CENX

Century Aluminum

$13.64

-0.36 (-2.57%)

NFLX

Netflix

$152.20

-0.88 (-0.57%)

FB

Facebook

$150.25

2.55 (1.73%)

AMZN

Amazon.com

$924.99

6.61 (0.72%)

GOOG

Alphabet

$905.96

31.71 (3.63%)

GOOGL

Alphabet Class A

$924.52

33.08 (3.71%)

CMCSA

Comcast

$39.19

-0.4 (-1.01%)

CMCSK

Comcast

VZ

Verizon

$45.91

-0.76 (-1.63%)

T

AT&T

$39.63

-0.28 (-0.70%)

CYH

Community Health

$8.61

0.18 (2.14%)

HCA

HCA Holdings

$84.21

0.77 (0.92%)

LPNT

LifePoint

$62.15

1.4 (2.30%)

THC

Tenet

$15.67

0.2 (1.29%)

UHS

Universal Health

$120.76

2.55 (2.16%)

AET

Aetna

$135.07

1.09 (0.81%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

CNC

Centene

$74.40

1.45 (1.99%)

CI

Cigna

$156.37

0.16 (0.10%)

HNT

Health Net

HUM

Humana

$221.98

3.31 (1.51%)

MOH

Molina Healthcare

$49.79

1.16 (2.39%)

UNH

UnitedHealth

$174.88

0.25 (0.14%)

WCG

WellCare

$153.41

0.03 (0.02%)

HRB

H&R Block

$24.79

0.52 (2.14%)

INTU

Intuit

$125.21

-0.4 (-0.32%)

ATW

Atwood Oceanics

$7.83

-0.01 (-0.13%)

DO

Diamond Offshore

$14.42

-0.07 (-0.48%)

NE

Noble Corp.

$4.80

-0.03 (-0.62%)

NADL

North Atlantic Drilling

$2.53

0.18 (7.66%)

PACD

Pacific Drilling

$1.70

-0.07 (-3.95%)

RDC

Rowan Companies

$14.07

0.07 (0.50%)

SDRL

Seadrill

$0.69

0.0221 (3.31%)

FSLR

First Solar

$29.55

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 04

    May

  • 05

    May

  • 05

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 13

    Jun

KBR

KBR

$14.05

-1.43 (-9.24%)

18:47
04/28/17
04/28
18:47
04/28/17
18:47
Hot Stocks
KBR issues statement on SFO investigation »

KBR made the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SMMT

Summit Therapeutics

$11.00

-0.4 (-3.51%)

18:32
04/28/17
04/28
18:32
04/28/17
18:32
Hot Stocks
Summit Therapeutics publishes results from CoDIFy trial online »

Summit Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.83

0.85 (3.54%)

18:14
04/28/17
04/28
18:14
04/28/17
18:14
Hot Stocks
Takeda says FDA grants accelerated approval of ALUNBRIG »

Takeda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

18:07
04/28/17
04/28
18:07
04/28/17
18:07
Hot Stocks
FDIC named receiver of First NBC Bank »

First NBC Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGBK

Stonegate Bank

$45.90

-0.52 (-1.12%)

17:47
04/28/17
04/28
17:47
04/28/17
17:47
Earnings
Stonegate Bank reports Q1 non-GAAP EPS 56c, consensus 57c »

Reports Q1 NII $25.89M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PROV

Provident Financial

$19.23

-0.03 (-0.16%)

17:45
04/28/17
04/28
17:45
04/28/17
17:45
Hot Stocks
Provident Financial announces extension of stock repurchase plan »

Provident Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

YGE

Yingli Green Energy

$2.66

-0.03 (-1.12%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Yingli Green Energy files extension for 2016 Form 20-F filing »

Yingli Green Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Breaking Hot Stocks news story on Edgewell Personal Care »

Gabelli raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.